Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475745 | 1.00 | TDP1 (0.46) | TDP1CYP11B1CYP11B2HTTLMNA | |
| SCHEMBL1255701 | 0.80 | HTT (0.52) | TDP1CYP11B1CYP11B2HTTLMNA | |
| SCHEMBL30475094 | 0.80 | HTT (0.52) | TDP1CYP11B1CYP11B2HTTLMNA | |
| SCHEMBL1255703 | 0.80 | HTT (0.52) | TDP1CYP11B1CYP11B2HTTLMNA | |
| SCHEMBL1177889 | 0.76 | CYP2D6 (0.49) | TDP1TSHROPRM1OPRK1OGFRL1 | |
| SCHEMBL6969625 | 0.74 | TDP1 (0.58) | TDP1CYP11B1CYP11B2HTTLMNA | |
| SCHEMBL4295876 | 0.72 | EGLN3 (0.46) | TDP1CYP11B1CYP11B2LMNATNF | |
| SCHEMBL4295875 | 0.72 | EGLN3 (0.46) | TDP1CYP11B1CYP11B2LMNATNF | |
| SCHEMBL23499140 | 0.72 | TDP1 (0.54) | TDP1CYP11B1CYP11B2HTTLMNA | |
| SCHEMBL29668645 | 0.72 | TDP1 (0.54) | TDP1CYP11B1CYP11B2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | TDP1 538/4885CYP11B1 3285/4885CYP11B2 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.